SAB BIOTHERAPEUTICS INC (SABS) Stock Fundamental Analysis

NASDAQ:SABS • US78397T2024

3.675 USD
+0.1 (+2.94%)
Last: Feb 23, 2026, 03:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

SABS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. While SABS seems to be doing ok healthwise, there are quite some concerns on its profitability. SABS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year SABS has reported negative net income.
  • SABS had a negative operating cash flow in the past year.
  • SABS had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: SABS reported negative operating cash flow in multiple years.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • The Return On Assets of SABS (-11.65%) is better than 83.69% of its industry peers.
  • Looking at the Return On Equity, with a value of -12.94%, SABS belongs to the top of the industry, outperforming 87.33% of the companies in the same industry.
Industry RankSector Rank
ROA -11.65%
ROE -12.94%
ROIC N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

  • SABS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SABS has been increased compared to 1 year ago.
  • SABS has a worse debt/assets ratio than last year.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • SABS has an Altman-Z score of 4.73. This indicates that SABS is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of SABS (4.73) is better than 72.17% of its industry peers.
  • A Debt/Equity ratio of 0.02 indicates that SABS is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.02, SABS perfoms like the industry average, outperforming 44.34% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 4.73
ROIC/WACCN/A
WACC8.68%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 10.50 indicates that SABS has no problem at all paying its short term obligations.
  • SABS's Current ratio of 10.50 is amongst the best of the industry. SABS outperforms 83.49% of its industry peers.
  • SABS has a Quick Ratio of 10.50. This indicates that SABS is financially healthy and has no problem in meeting its short term obligations.
  • SABS's Quick ratio of 10.50 is amongst the best of the industry. SABS outperforms 83.49% of its industry peers.
Industry RankSector Rank
Current Ratio 10.5
Quick Ratio 10.5
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 48.62% over the past year.
  • The Revenue for SABS has decreased by -92.42% in the past year. This is quite bad
  • SABS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -72.10% yearly.
EPS 1Y (TTM)48.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.61%
Revenue 1Y (TTM)-92.42%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 13.98% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 125.90% on average over the next years. This is a very strong growth
EPS Next Y87.71%
EPS Next 2Y35.41%
EPS Next 3Y23.24%
EPS Next 5Y13.98%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-24.65%
Revenue Next 5Y125.9%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SABS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • SABS's earnings are expected to grow with 23.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.41%
EPS Next 3Y23.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SABS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (2/23/2026, 3:46:06 PM)

3.675

+0.1 (+2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners59.15%
Inst Owner Change28.09%
Ins Owners1.87%
Ins Owner Change13.15%
Market Cap174.97M
Revenue(TTM)114.70K
Net Income(TTM)-21.37M
Analysts85.71
Price Target9.56 (160.14%)
Short Float %5.09%
Short Ratio5.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.34%
Min EPS beat(2)-34.25%
Max EPS beat(2)70.94%
EPS beat(4)2
Avg EPS beat(4)20.03%
Min EPS beat(4)-34.25%
Max EPS beat(4)70.94%
EPS beat(8)4
Avg EPS beat(8)-35.61%
EPS beat(12)7
Avg EPS beat(12)-25.29%
EPS beat(16)10
Avg EPS beat(16)-40.08%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-76.57%
Min Revenue beat(4)-100%
Max Revenue beat(4)-6.29%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.13%
EPS NQ rev (1m)-7.02%
EPS NQ rev (3m)62.07%
EPS NY rev (1m)41.94%
EPS NY rev (3m)80.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1525.43
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-3.03
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0
BVpS3.47
TBVpS3.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.65%
ROE -12.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.5
Quick Ratio 10.5
Altman-Z 4.73
F-Score3
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)828.01%
Cap/Sales(3y)14.46%
Cap/Sales(5y)16.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.61%
EPS Next Y87.71%
EPS Next 2Y35.41%
EPS Next 3Y23.24%
EPS Next 5Y13.98%
Revenue 1Y (TTM)-92.42%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-24.65%
Revenue Next 5Y125.9%
EBIT growth 1Y16.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-178.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-183.73%
OCF growth 3YN/A
OCF growth 5YN/A

SAB BIOTHERAPEUTICS INC / SABS FAQ

Can you provide the ChartMill fundamental rating for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SABS.


What is the valuation status for SABS stock?

ChartMill assigns a valuation rating of 1 / 10 to SAB BIOTHERAPEUTICS INC (SABS). This can be considered as Overvalued.


What is the profitability of SABS stock?

SAB BIOTHERAPEUTICS INC (SABS) has a profitability rating of 2 / 10.


What is the earnings growth outlook for SAB BIOTHERAPEUTICS INC?

The Earnings per Share (EPS) of SAB BIOTHERAPEUTICS INC (SABS) is expected to grow by 87.71% in the next year.